Illustrative decision brief
Tissue evidence or distribution imaging?
A fictional antibody program with enough budget for one follow-up study.
- Decision owner
- Sponsor development team
- Program
- Preclinical antibody for a solid tumor indication
- Decision window
- Before the next preclinical portfolio review
What is known
The program has an activity signal in a target-positive model. Its supporting expression data come from a small, selected tissue set. The team has yet to establish how well that set represents its proposed indication.
Options considered
| Study | Question resolved | Priority |
|---|---|---|
| Independent tissue review | How well does the available expression evidence cover the intended tumor population? | Prioritize |
| Distribution imaging | Where does the labeled candidate accumulate in the selected model? | Defer |
| Repeat the activity study | Is the signal repeatable within the same model? | Revisit if reproducibility is questioned |
Recommendation and review condition
Review an independent tissue set first. For this program, evidence about the intended population is more likely to change the indication decision. Revisit imaging if expression is sufficiently consistent but delivery remains uncertain. If sample quality prevents a meaningful comparison, pause and reassess specimen feasibility.
Development decision remains with the sponsor.